Navigation Links
Clinical Genomics Continues Progress in Developing Biomarker Portfolio for Colorectal Cancer Testing
Date:4/29/2009

SYDNEY, April 29 /PRNewswire/ -- Clinical Genomics Pty Ltd, an Australian biotechnology company, announced today that Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, has agreed to provide milestone payments over the next two years to Clinical Genomics to further develop its portfolio of gene-based biomarkers associated with early onset of colorectal cancer. Clinical Genomics was awarded the payments after successfully achieving key research and development goals. Under terms of a worldwide license agreement, Quest Diagnostics has exclusive rights to the biomarkers for use in developing a test as an aid in detecting precancerous and cancerous colorectal tumors in conjunction with other clinical findings. Additional financial terms were not disclosed.

Clinical Genomics, in collaboration with Flinders University (South Australia) and the Australian Government's Commonwealth Scientific and Industrial Research Organization (CSIRO, Australia), has discovered molecular markers that show promise as aids in detection of both colorectal cancer and precancerous adenomas.

"Quest Diagnostics is at the forefront of efforts to develop and offer cancer testing innovations, including gene-based blood tests and fecal immunochemical tests associated with the detection of colorectal cancer," said Lawrence LaPointe, CEO of Clinical Genomics. "We are excited that as the world's leader in cancer diagnostics, Quest Diagnostics appreciates the potential of our proprietary biomarkers to form the basis for a laboratory test that one day may aid the detection of early-stage colorectal cancer."

Colorectal cancer is the second most common cause of cancer related death of both men and women in the United States and Australia. Colorectal cancer is largely treatable when detected in the early stages. Yet, due to low screening rates, fewer than 40 percent of cases are caught early [1].

In 2006, Quest Diagnostics acquired Enterix Inc., manufacturer of the FDA- cleared InSure(R) fecal immunochemical test (FIT) for aiding the detection of colorectal cancer based on stool testing. Quest Diagnostics also made an equity investment in Clinical Genomics, which was formed as a spin off from Enterix's research and development.

[1]American Cancer Society

About Clinical Genomics

Clinical Genomics is a Sydney-based biotechnology company formed in 2006 to exploit the patented and patent-pending gene expression biomarkers of colorectal cancer discovered by its founders and Flinders University in 2001. Clinical Genomics continues to work closely with Flinders University and CSIRO to advance the development of products that will improve the detection and management of this serious disease. Additional information is available at: www.clinicalgenomics.com.


    Contact: (For Clinical Genomics)
    Lawrence LaPointe,
    +61 4 0099 5027,
    larry@clinicalgenomics.com


'/>"/>
SOURCE Clinical Genomics Pty Ltd
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Stallergenes S.A.: Positive Results From a Phase IIb/III Clinical Trial on the House Dust Mite Desensitization Tablet
2. Merz Pharmaceuticals Announces Results of Three Clinical Trials With NT-201 (Botulinum Neurotoxin Type A Free From Complexing Proteins) in Movement Disorder Patients
3. Dendreon Presents Preclinical Data Demonstrating Activity of TRPM8 Agonist, D-3263, in Benign Prostatic Hyperplasia
4. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
5. Affitech-Discovered Anti-PS Antibodies in Development by Peregrine Pharmaceuticals Show Excellent Functionality in Preclinical Studies
6. Clinical Update - Debio 025 in Hepatitis C
7. Schering-Plough Highlights Hepatitis C Clinical Data Presentations at the European Association for the Study of the Liver (EASL) Annual Meeting
8. Roche and Pharmasset Initiate Phase IIb Clinical Trial of R7128, Most Advanced Nucleoside Polymerase Inhibitor in Development for Chronic Hepatitis C
9. HeartWare International Clinical Trial Shows 90% Survival at 180 Days
10. Micromet Presents Preclinical Data Showing Activity of Erbitux and Vectibix Based BiTE Antibodies against KRAS- and BRAF-mutated Human Colorectal Cancer Cells
11. NovaBay(R) Pharmaceuticals Enters into Agreement to Broaden Intellectual Property Estate and Expand Clinical Opportunities for Its Aganocide(R) Compounds
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ANDOVER, Mass. and SAN CLEMENTE, Calif. ... California -based mobile pulmonary function testing company, is now ... portable PFT devices developed by ndd Medical Technologies , Inc. ... PFT testing done in hospital-based labs.  Thanks to ndd,s EasyOne PRO ... CA , can get any needed testing done in the ...
(Date:6/24/2016)... , Belgium , June ... MKT: VNRX), today announced the appointment of Dr. ... of Directors as a Non-Executive Director, effective June ... Company,s Audit, Compensation and Nominations and Governance Committees.  ... Dr. Futcher will provide independent expertise and strategic ...
(Date:6/23/2016)... 2016 Any dentist who has made an implant ... process. Many of them do not even offer this as ... high laboratory costs involved. And those who ARE able to ... a high cost that the majority of today,s patients would ... Parsa Zadeh , founder of Dental Evolutions Inc. and inventor ...
Breaking Medicine Technology:
(Date:6/26/2016)... PLAINSBORO, N.J. (PRWEB) , ... June 27, 2016 , ... ... same sources, yet in many ways they remain in the eye of the beholder, ... Oncology (EBO), a publication of The American Journal of Managed Care. For the full ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... they have been diagnosed with endometriosis. These women need a treatment plan to ... a comprehensive approach that can help for preservation of fertility and ultimately achieving ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/24/2016)... ... 24, 2016 , ... A recent article published June 14 on ... article goes on to state that individuals are now more comfortable seeking to undergo ... such as calf and cheek reduction. The Los Angeles area medical group, Beverly Hills ...
(Date:6/24/2016)... ... 24, 2016 , ... Global law firm Greenberg Traurig, P.A. announced that 20 ... by their peers for this recognition are considered among the top 2 percent of ... honors as members of this year’s Legal Elite Hall of Fame: Miami Shareholders ...
Breaking Medicine News(10 mins):